You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.


Go back

How to prescribe Seretide

Seretide indications

Seretide in asthma

Seretide is indicated in the regular treatment of patients aged 4 and over with asthma, where use of a combination product (long-acting ß2–agonist, LABA, and inhaled corticosteroid, ICS) is appropriate:

  • Patients not adequately controlled on both ICS and 'as-needed' short-acting ß2-agonist (SABA).
  • Patients already adequately controlled on both ICS and LABA. 1

Seretide in COPD

Seretide 500 Diskus is indicated for the symptomatic treatment of COPD patients with FEV1 <60% predicted normal (pre-bronchodilator) with repeated exacerbations and significant symptoms despite regular bronchodilator therapy 1

Inhalers and devices

Inhaler technique

Seretide Evohaler is the only salmeterol/fluticasone propionate combination licensed for use with the Volumatic spacer device.

Using an inhaler is a skill that must be learnt and maintained in order for medication to be delivered effectively. Poor inhaler technique may lead to poor asthma control, increased risk of exacerbations and increased risk of adverse effects. Additionally, different spacers are associated with different systemic absorption of fluticasone propionate, so for safety/tolerability reasons patients should not switch from one spacer device to another. All healthcare professionals should be encouraged to assess asthma control, adherence and inhaler technique at every visit 1.

In order to support this important goal of disease management we have provided leaflets and videos designed to help you to help your patients with correct inhaler technique.

Inhaler technique leaflets

Inhaler technique videos 

How to use your Evohaler:

Video player requires JavaScript enabled. You can download this video here:

How to use your Evohaler with a spacer:

Video player requires JavaScript enabled. You can download this video here:

Seretide in paediatric patients

For further information on how Seretide offers an effective asthma treatment for children aged four years and older, see our paediatrics page.


Seretide safety and tolerability

For all Seretide safety and tolerability information please review the Seretide Summary of Product Characteristics. The following sections contain the safety and tolerability information:

4.3 Contraindications

4.4 Special warnings and precautions for use

4.5 Interaction with other medicinal products and other forms of interaction

4.6 Fertility, pregnancy and lactaction

4.7 Effects on ability to drive and use machines

4.8 Undesirable affects

4.9 Overdose


  1. Seretide Diskus Summary of Product Characteristics (Date accessed - 03 July 2015)
  2. Seretide Evohaler Summary of Product Characteristics (Date accessed - 03 July 2015)
  3. Global strategy for asthma management and prevention, 2016; accessed 10th May 2016

Seretide, Evohaler and Diskus are registered trademarks of the GlaxoSmithKline Group of Companies